BridgeBio Oncology Therapeutics(BBOT)
SOUTH SAN FRANCISCO, CABiotechnology
Focus: BridgeBio Oncology Therapeutics is a public biotech company focused on RAS-targeted small molecule oncology therapeutics, currently in early-stage clinical development with a pre-revenue pipeline.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
6-1 this month
Stable — net -1 jobs in 30d
1 added, 2 removed. Backfill posture.
Should You Work at BridgeBio Oncology Therapeutics?
AI assessmentBridgeBio Oncology is a speculative early-stage play suited for risk-tolerant scientists seeking cutting-edge RAS biology work, but with material cash runway and de-risking uncertainty.
Why Work Here
- Opportunity to work on differentiated RAS-targeted small molecules, a high-value oncology space with significant unmet need
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Help build intelligence for BridgeBio Oncology Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.